← Back to Search

Smoking Cessation Program for Lung Cancer Prevention

N/A
Recruiting
Led By Matthew Triplette
Research Sponsored by Fred Hutchinson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
AIM 1, COMMUNITY ORGANIZATION LEADERS: Age minimum of 18
As of Jan 2022: aged 50-80 years, at least 20 pack-year smoking history, and currently smoke tobacco cigarettes [as this intervention is based around current cigarette smokers (as defined above)], former cigarette smokers not included in this Aim
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This trial is developing a tailored screening and smoking cessation program for the LGBTQ community in Seattle to help them quit smoking and prevent lung cancer.

Who is the study for?
This trial is for LGBTQ individuals in Seattle aged 50-80 who currently smoke or have a history of heavy smoking, aiming to improve lung cancer screening and cessation support. Healthcare providers serving this community and leaders involved with LGBTQ organizations are also eligible.Check my eligibility
What is being tested?
The program being tested includes patient navigation, questionnaires, a smoking cessation intervention, and carbon monoxide measurement to tailor lung cancer screening and help the LGBTQ community quit smoking.See study design
What are the potential side effects?
There may not be direct side effects from participating as it's more about support and monitoring rather than medication. However, quitting smoking can lead to withdrawal symptoms like irritability, cravings, or difficulty concentrating.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am at least 18 years old.
Select...
I am between 50-80 years old, have smoked for 20 years or more, and currently smoke.
Select...
I am at least 18 years old and provide care for LGBTQ patients.
Select...
I qualify for a lung cancer screening without any cost based on US guidelines.
Select...
I am between 50 and 80 years old.
Select...
I am currently smoking or have smoked within the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability of patient navigation and smoking cessation interventions (Aim 3)
Effectiveness of navigation visit(s): knowledge (Aim 3)
Effectiveness of navigation visit(s): smoking cessation (Aim 3)
+3 more

Side effects data

From 2015 Phase 2 trial • 58 Patients • NCT01214187
28%
Headache
28%
Dyspnea
24%
Cough
17%
Upper respiratory tract infection
14%
Nasal Congestion
10%
Dizziness
10%
Fatigue
10%
Productive Cough
7%
Pneumonia
7%
IPF progression
7%
Diarrhea
7%
Wheezing
7%
Gastroesophageal reflux disease
3%
Acute pancreatitis
3%
Worsening Cirrhosis
3%
Acute Coronary Syndrome
3%
Worsening of Shortness of Breath
3%
Pulmonary Fibrosis Related Death
100%
80%
60%
40%
20%
0%
Study treatment Arm
Oxygen 21%
Carbon Monoxide Inhalation

Trial Design

1Treatment groups
Experimental Treatment
Group I: Health services research (patient navigation intervention)Experimental Treatment4 Interventions
Participants receive a patient navigation intervention consisting of a series of points of contact (mostly via telephone) between the PN/TTS and includes: 1) An introduction and enrollment in LCS, 2) facilitation of a SDM visit with the LCS-dedicated nurse practitioner, 3) individual assessment of barriers and facilitators to in-person low-dose CT screening, 4) explanation of results and needed follow-up, and 5) follow-up reminders. Participants also undergo carbon monoxide measurement by exhaling into a disposable monitor for 10 seconds at the initial visit and the post-intervention visit. The PN may also provide an intervention for smoking cessation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient Navigation
2017
Completed Phase 2
~38910
Smoking Cessation Intervention
2005
N/A
~1800

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer CenterLead Sponsor
555 Previous Clinical Trials
1,334,665 Total Patients Enrolled
LUNGevity FoundationOTHER
7 Previous Clinical Trials
1,585 Total Patients Enrolled
Matthew TriplettePrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium

Media Library

Lung Cancer Research Study Groups: Health services research (patient navigation intervention)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open for this research project?

"Affirmative. The information hosted on clinicaltrials.gov establishes that this medical trial, which was initially posted on December 10th 2022, is actively seeking participants. Approximately 50 individuals need to be enrolled from a single location."

Answered by AI

To what extent are participants being monitored in this research project?

"Affirmative. The clinical trial portal states that the study, which was originally posted on December 10th 2022, is currently welcoming participants. It requires 50 volunteers to be enrolled at a single medical centre."

Answered by AI
~3 spots leftby May 2024